Menu
MSE PRO (1R,3R,5S)-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride, ≥98.0% Purity - MSE Supplies LLC

MSE PRO (1R,3R,5S)-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride, ≥98.0% Purity

  • £18100
  • Save £2000


MSE PRO™ (1R,3R,5S)-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride, ≥98.0% Purity

MSE PRO™ (1R,3R,5S)-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride is a chiral bicyclic compound containing a nitrogen atom and a hydroxy group, existing as the hydrochloride salt. The presence of the hydroxy group and the rigid bicyclic ring system make this compound a versatile synthetic intermediate for the preparation of various nitrogen-containing heterocyclic compounds and pharmaceutically active molecules. As a chiral building block, it can be employed in enantioselective synthesis, enabling the construction of optically pure drugs, agrochemicals, and other biologically active compounds where stereochemical purity is crucial for potency and selectivity.

 MSE Supplies offers various N-heterocyclic drug small molecules and other chemical reagents. Please contact us for bulk orders.

Technical Specifications:

CAS No. 14383-51-8
Chemical name (1R,3R,5S)-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride
Synonym(s)

· Nortropine hydrochloride

· endo-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride

Molecular formula C7H14ClNO        
Pack size

25 g (CM1377)

Molecular weight 163.65 g/mol
Purity ≥98.0% (NMR)
Melting point 231-237°C (decomposition) 
Appearance White to off-white solid
Storage 
2-8°C, sealed storage, away from moisture


References:

[1] Varty, G. B., Lu, S. X., Morgan, C. A., Cohen-Williams, M. E., Hodgson, R. A., Smith-Torhan, A., ... & Carey, G. J. (2008). The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis (2-methylphenyl) methyl]-3-phenyl-8-azabicyclo [3.2. 1] octan-3-ol (SCH 221510). Journal of Pharmacology and Experimental Therapeutics326(2), 672-682.

[2] Millard, M., Kilian, J., Ozenil, M., Mogeritsch, M., Schwingenschlögl-Maisetschläger, V., Holzer, W., ... & Pichler, V. (2023). Design, synthesis and preclinical evaluation of muscarine receptor antagonists via a scaffold-hopping approach. European Journal of Medicinal Chemistry262, 115891.